PE20161224A1 - Compuestos de azabenzofurano que contienen ciano para el tratamiento de la hepatitis c - Google Patents
Compuestos de azabenzofurano que contienen ciano para el tratamiento de la hepatitis cInfo
- Publication number
- PE20161224A1 PE20161224A1 PE2016001648A PE2016001648A PE20161224A1 PE 20161224 A1 PE20161224 A1 PE 20161224A1 PE 2016001648 A PE2016001648 A PE 2016001648A PE 2016001648 A PE2016001648 A PE 2016001648A PE 20161224 A1 PE20161224 A1 PE 20161224A1
- Authority
- PE
- Peru
- Prior art keywords
- treatment
- fluorophenyl
- hepatitis
- methyl
- phenyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 208000006454 hepatitis Diseases 0.000 title 1
- 231100000283 hepatitis Toxicity 0.000 title 1
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 241000711549 Hepacivirus C Species 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 125000001309 chloro group Chemical group Cl* 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invencion se refiere a compuestos de la formula I o sales farmaceuticamente aceptables donde Z es C-R5 o N; R0 es H; R1 es metilo; R2 es fenilo sustituido con 0-2 halo o metoxi, o es para sustituido con W-Ar; W es -O- o -NH-; Ar es fenilo o para-halofenilo; R3 es hidrogeno, fluoro o cloro; R4, R5 y R6 son H, halos, entre otros ; R7a, R7b son H, Ar1, entre otros o R7a y R7b forman un anillo carbociclico de 3-7 elementos; R8 es H ; Ar1 es fenilo, entre otros; R9 es hidrogeno, halo , entre otros. Son compuestos preferentes (R)-5-(3-((1-ciano-1-ciclopropiletil)carbamoil)-4-fluorofenil)-2-(4-fluorofenil)-N-metil-6-(3,3,3-trifluoropropil)furo[2,3-b]piridin-3-carboxamida; (S)-5-(3-((1-ciano-1-ciclopropiletil)carbamoil)-4-fluorofenil)-2-(4-fluorofenil)-N-metil-6-(3,3,3-trifluoropropil)furo[2,3-b]piridin-3-carboxamida. Tambien se refiere a una composicion y un metodo de tratamiento. Dichos compuestos tienen actividad contra el virus de la hepatitis C, siendo utiles en el tratamiento de pacientes infectados con este virus
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461968763P | 2014-03-21 | 2014-03-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20161224A1 true PE20161224A1 (es) | 2016-11-12 |
Family
ID=52808191
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2016001648A PE20161224A1 (es) | 2014-03-21 | 2015-03-20 | Compuestos de azabenzofurano que contienen ciano para el tratamiento de la hepatitis c |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US9249152B2 (es) |
| EP (1) | EP3119785B1 (es) |
| JP (1) | JP2017509700A (es) |
| KR (1) | KR20160126085A (es) |
| CN (1) | CN106459070A (es) |
| AR (1) | AR099820A1 (es) |
| AU (1) | AU2015231139A1 (es) |
| CA (1) | CA2943526A1 (es) |
| CL (1) | CL2016002361A1 (es) |
| EA (1) | EA201691777A1 (es) |
| ES (1) | ES2688554T3 (es) |
| IL (1) | IL247830A0 (es) |
| MX (1) | MX2016012104A (es) |
| PE (1) | PE20161224A1 (es) |
| SG (1) | SG11201607750PA (es) |
| TW (1) | TW201620914A (es) |
| WO (1) | WO2015143255A1 (es) |
| ZA (1) | ZA201606478B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015143256A1 (en) * | 2014-03-21 | 2015-09-24 | Bristol-Myers Squibb Company | Cyanoamino (aza)benzofuran compounds for the treatment of hepatitis c |
| KR20180086247A (ko) * | 2015-12-07 | 2018-07-30 | 플렉시콘 인코퍼레이티드 | 키나제 조절을 위한 화합물 및 방법과 이들에 대한 징후 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20050065661A (ko) | 2002-11-01 | 2005-06-29 | 비로파마 인코포레이티드 | 벤조푸란 화합물, 조성물 및 ｃ형 간염 바이러스 감염 및관련 질병의 치료 및 예방 방법 |
| MX2010004623A (es) | 2008-02-14 | 2010-06-07 | Hoffmann La Roche | Compuestos heterociclicos antiviricos. |
| US8048887B2 (en) * | 2008-09-11 | 2011-11-01 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US7994171B2 (en) * | 2008-09-11 | 2011-08-09 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US8198449B2 (en) * | 2008-09-11 | 2012-06-12 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| JP5572725B2 (ja) | 2010-03-10 | 2014-08-13 | ブリストル−マイヤーズ スクイブ カンパニー | Ｃ型肝炎の処置のための化合物 |
| PH12013500770A1 (en) | 2010-10-26 | 2018-01-17 | Presidio Pharmaceuticals Inc | Inhibitors of hepatitis c virus |
-
2015
- 2015-03-20 EP EP15714137.5A patent/EP3119785B1/en not_active Not-in-force
- 2015-03-20 AU AU2015231139A patent/AU2015231139A1/en not_active Abandoned
- 2015-03-20 EA EA201691777A patent/EA201691777A1/ru unknown
- 2015-03-20 JP JP2017501122A patent/JP2017509700A/ja active Pending
- 2015-03-20 AR ARP150100859A patent/AR099820A1/es unknown
- 2015-03-20 CA CA2943526A patent/CA2943526A1/en not_active Abandoned
- 2015-03-20 SG SG11201607750PA patent/SG11201607750PA/en unknown
- 2015-03-20 TW TW104109071A patent/TW201620914A/zh unknown
- 2015-03-20 PE PE2016001648A patent/PE20161224A1/es not_active Application Discontinuation
- 2015-03-20 US US14/663,497 patent/US9249152B2/en active Active
- 2015-03-20 CN CN201580024715.3A patent/CN106459070A/zh active Pending
- 2015-03-20 ES ES15714137.5T patent/ES2688554T3/es active Active
- 2015-03-20 KR KR1020167028891A patent/KR20160126085A/ko not_active Withdrawn
- 2015-03-20 MX MX2016012104A patent/MX2016012104A/es unknown
- 2015-03-20 WO PCT/US2015/021638 patent/WO2015143255A1/en not_active Ceased
-
2016
- 2016-09-15 IL IL247830A patent/IL247830A0/en unknown
- 2016-09-20 CL CL2016002361A patent/CL2016002361A1/es unknown
- 2016-09-20 ZA ZA2016/06478A patent/ZA201606478B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2016002361A1 (es) | 2017-04-21 |
| WO2015143255A1 (en) | 2015-09-24 |
| US20150266886A1 (en) | 2015-09-24 |
| EP3119785A1 (en) | 2017-01-25 |
| IL247830A0 (en) | 2016-11-30 |
| EA201691777A1 (ru) | 2016-12-30 |
| CN106459070A (zh) | 2017-02-22 |
| TW201620914A (zh) | 2016-06-16 |
| JP2017509700A (ja) | 2017-04-06 |
| MX2016012104A (es) | 2016-12-09 |
| AR099820A1 (es) | 2016-08-17 |
| CA2943526A1 (en) | 2015-09-24 |
| US9249152B2 (en) | 2016-02-02 |
| AU2015231139A1 (en) | 2016-11-03 |
| ES2688554T3 (es) | 2018-11-05 |
| KR20160126085A (ko) | 2016-11-01 |
| SG11201607750PA (en) | 2016-10-28 |
| ZA201606478B (en) | 2018-05-30 |
| EP3119785B1 (en) | 2018-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201890200A1 (ru) | Производные циклизированного сульфамоилариламида и их применение в качестве лекарственных препаратов для лечения гепатита b | |
| PE20170127A1 (es) | Indazol-3-carboxamidas 5-sustituidas y preparacion y uso de las mismas | |
| EA201591890A1 (ru) | Производные n-фенилкарбоксамида и их применение в качестве лекарственных препаратов для лечения гепатита b | |
| MX2021013075A (es) | Oxisteroles y metodos de uso de los mismos. | |
| EA201790389A1 (ru) | Пирролопиримидиновые соединения, используемые в качестве агониста tlr7 | |
| EA201791256A1 (ru) | Производные хиназолина, применяемые для лечения вич | |
| MX2017001637A (es) | 2-(morfolin-4-il)-1,7-naftiridinas. | |
| EA201592200A1 (ru) | Производные сульфамоилпирроламида и их применение в качестве медикаментов для лечения гепатита b | |
| EA201591586A1 (ru) | Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b | |
| EA201791304A1 (ru) | Производные изохинолина для лечения вич | |
| EA201590450A1 (ru) | Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b | |
| MX2019003143A (es) | Compuesto heterociclico sustituido con alquinilo, su metodo de preparacion y su uso medico. | |
| EA201692249A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
| EA201891267A1 (ru) | Фармацевтическая композиция, содержащая действенный ингибитор urat1 | |
| EA201692266A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
| EA201590022A1 (ru) | Новые производные 1,3-дигидро-2h-бензимидазол-2-она, замещенные гетероциклами, в качестве противовирусных средств против респираторного синцитиального вируса | |
| PH12018500378B1 (en) | Novel annelated phenoxyacetamides | |
| MX390051B (es) | Antagonistas de ep4. | |
| EA201790726A1 (ru) | Фармацевтическая композиция для лечения язвенного колита | |
| EA201692300A1 (ru) | Производные карбоксамида | |
| JOP20190086A1 (ar) | مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب | |
| JOP20190050A1 (ar) | مثبطات دوبامين-b-هيدروكسيلاز تخترق حاجز المخ الدموي | |
| EA201692298A1 (ru) | Производные карбоксамидов | |
| PE20161224A1 (es) | Compuestos de azabenzofurano que contienen ciano para el tratamiento de la hepatitis c | |
| EA201890896A1 (ru) | Твердый препарат для перорального применения, содержащий аморфный солифенацин, и способ его получения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |